Review



vascular endothelial growth factor  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems vascular endothelial growth factor
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Vascular Endothelial Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 440 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/Human+VEGF+DuoSet+ELISA/pmc12926579-106-14-25
    Average 96 stars, based on 440 article reviews
    vascular endothelial growth factor - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing"

    Article Title: Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing

    Journal: Bioactive Materials

    doi: 10.1016/j.bioactmat.2026.02.004

    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Figure Legend Snippet: Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

    Techniques Used: Activity Assay, Gene Expression, Activation Assay, Inhibition, Marker, Expressing

    Pro-inflammatory (M1) macrophages are driven towards an anti-inflammatory (M2) phenotype on CG-155-i scaffolds. A-B) Assessment of cell viability through metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Scaffold-mediated inhibition of miRNA-155 in pro-inflammatory macrophages maintains SHIP1 and SOCS1 upregulation despite the enhanced inflammatory environment. F-H) NOS2 expression shows a trending decrease while CD80 and CD86 levels are downregulated on the CG-155-i scaffolds. I-J) Scaffold-mediated miRNA-155 inhibition does not significantly alter ARG1 expression whereas CD206 is still upregulated, highlighted an M2 macrophage polarisation despite the inflammatory cues. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Figure Legend Snippet: Pro-inflammatory (M1) macrophages are driven towards an anti-inflammatory (M2) phenotype on CG-155-i scaffolds. A-B) Assessment of cell viability through metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Scaffold-mediated inhibition of miRNA-155 in pro-inflammatory macrophages maintains SHIP1 and SOCS1 upregulation despite the enhanced inflammatory environment. F-H) NOS2 expression shows a trending decrease while CD80 and CD86 levels are downregulated on the CG-155-i scaffolds. I-J) Scaffold-mediated miRNA-155 inhibition does not significantly alter ARG1 expression whereas CD206 is still upregulated, highlighted an M2 macrophage polarisation despite the inflammatory cues. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

    Techniques Used: Activity Assay, Inhibition, Expressing

    Secretome from macrophages cultured on CG-155-i scaffolds induces anti-inflammatory responses on endothelial cells. A) Cytokine profile analysis revealed an increased release of pro-angiogenic and anti-inflammatory growth factors from macrophages on CG-155-i scaffolds. B-E) Endothelial cells exposed to M0 macrophage secretome show a reduced expression of pro-inflammatory ICAM in the CG-155-i group. F-I) M1 macrophage secretome on endothelial cells elicits clear morphological changes and decreased ICAM intensity in the CG-155-i group. Scale bars = 100 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01.
    Figure Legend Snippet: Secretome from macrophages cultured on CG-155-i scaffolds induces anti-inflammatory responses on endothelial cells. A) Cytokine profile analysis revealed an increased release of pro-angiogenic and anti-inflammatory growth factors from macrophages on CG-155-i scaffolds. B-E) Endothelial cells exposed to M0 macrophage secretome show a reduced expression of pro-inflammatory ICAM in the CG-155-i group. F-I) M1 macrophage secretome on endothelial cells elicits clear morphological changes and decreased ICAM intensity in the CG-155-i group. Scale bars = 100 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01.

    Techniques Used: Cell Culture, Expressing

    Secretome from macrophages on CG-155-i scaffolds enhances endothelial cell migration and organisation into vascular-like structures under chronic-like conditions. A) Endothelial cells exposed to M1 macrophage secretome show reduced migration rates compared to M0 conditions. B-C) Analysis of migration profiles under M0 conditions did not reveal any clear differences in behaviour between treatment groups. D-E) Endothelial cell migration rate exposed to secretome from M1 macrophages on CG-155-i scaffolds result in faster cell migration compared to the negative and miRNA-free groups after 24 h. E) Endothelial cells show higher vascular-like organisation when exposed to M0 macrophage secretome. F-H) Secretome from CG-155-i scaffolds enables improved vascular-like complexity in both M0 and M1 conditions. Scale bars = 500 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p > 0.001, and ∗∗∗∗p < 0.0001.
    Figure Legend Snippet: Secretome from macrophages on CG-155-i scaffolds enhances endothelial cell migration and organisation into vascular-like structures under chronic-like conditions. A) Endothelial cells exposed to M1 macrophage secretome show reduced migration rates compared to M0 conditions. B-C) Analysis of migration profiles under M0 conditions did not reveal any clear differences in behaviour between treatment groups. D-E) Endothelial cell migration rate exposed to secretome from M1 macrophages on CG-155-i scaffolds result in faster cell migration compared to the negative and miRNA-free groups after 24 h. E) Endothelial cells show higher vascular-like organisation when exposed to M0 macrophage secretome. F-H) Secretome from CG-155-i scaffolds enables improved vascular-like complexity in both M0 and M1 conditions. Scale bars = 500 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p > 0.001, and ∗∗∗∗p < 0.0001.

    Techniques Used: Migration

    Related Articles

    Sandwich ELISA:

    Article Title: Serum Aquaporin-4 Antibody Status and TGF-β in Neuromyelitis Optica Spectrum Disorder: Impact on Astrocyte Function and Correlation with Disease Activity and Severity.
    Article Snippet: Concentrations of interleukins-1β (IL-1β), -8 (IL-8), -10 (IL-10) and 17-A (IL-17A) were accessed through a multiplex assay, using the Essential 4-Plex Human ProcartaPlexTM Panel 2 kit (Thermo Fisher Scientific Inc., Waltham, MA, USA; Cat# EPX040-10008-901) according to the manufacturer’s instructions, and readings were performed on a Luminex 200TM System (Merck KGaA, Darmstadt, Germany). .. Concentrations of Thrombospondin-1 and Vascular Endothelial Growth Factor (VEGF) were accessed through sandwich ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA; Cat# DVE00 and DTSP10). ..

    other:

    Article Title: Direct cell reprogramming by a designed agonist inducing HER2-FGFR proximity
    Article Snippet: Briefly, hiPSCs (WTC-11 human induced pluripotent stem cells) [Coriell, #GM25256] were seeded on 24-well plates coated with growth factor-reduced Matrigel [Corning, #356231] and cultured in mTeSR1 stem cell medium [StemCell Technologies, #85850] until cells reach confluence with media changes daily.

    Multiplex Assay:

    Article Title: Mesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera.
    Article Snippet: The exponential cell growth curve was plotted using the GraphPad Prism 6.0 (Dotmatics) software. .. Quantification of soluble immune and angiogenic mediators Supernatants from co-cultures of BM-MSCs and PBMCs at 1:10 ratio were used to quantify epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), Fms-related tyrosine kinase 3 ligand (Flt-3 L), interferon alpha (IFN-a), macrophagederived chemokine (MDC), interleukin 1 beta (IL-1b), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-a), and vascular endothelial growth factor (VEGF) using the multiplex human customized Magnetic Luminex Assay (R&D Systems), according to the manufacturer’s instructions. .. The samples were analyzed in a MX Luminex (MERCK) and the concentration was determined using xPONENT (Luminex, MERCK, Sigma-Aldrich).

    Article Title: Mesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera
    Article Snippet: The exponential cell growth curve was plotted using the GraphPad Prism 6.0 (Dotmatics) software. .. Supernatants from co-cultures of BM-MSCs and PBMCs at 1:10 ratio were used to quantify epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), Fms-related tyrosine kinase 3 ligand (Flt-3 L), interferon alpha (IFN-α), macrophage-derived chemokine (MDC), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), and vascular endothelial growth factor (VEGF) using the multiplex human customized Magnetic Luminex® Assay (R&D Systems), according to the manufacturer’s instructions. .. The samples were analyzed in a MX® Luminex (MERCK) and the concentration was determined using xPONENT (Luminex, MERCK, Sigma-Aldrich).

    Enzyme-linked Immunosorbent Assay:

    Article Title: A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome
    Article Snippet: The absorbance at 405 nm was measured via Infinite M200 microplate reader (Tecan). .. To analyze vascular endothelial growth factor (VEGF) and granulocyte colony-stimulating factor (G-CSF) secretion, we performed ELISA using the human VEGF Quantikine kit and Human G-CSF Quantikine Kit (R&D Systems, MN, USA; No.SVE00 and No.QK214). .. Briefly, 0.5 μg/mL VEGF antibody was added to each well of a 96-well polyvinyl microplate (R&D Systems) and stored at 4°C overnight.

    Article Title: Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis.
    Article Snippet: .. Measurement of soluble immunosuppressive factors The levels of soluble immunosuppressive factors, including matrix metalloproteinase (MMP)-1, MMP-2, and MMP-7, transforming growth factor-beta 1 (TGF-β1), hepatocyte growth factor (HGF), E-cadherin, vascular endothelial growth factor (VEGF), and angiopoietin-2 (ANGPT-2), were quantified [10-12,14-17]. https://doi.org/10.5230/jgc.2025.25.e46https://jgc-online.org Plasma and ascites supernatants were analyzed for these factors using commercially available ELISA kits (Quantikine; R&D Systems, Minneapolis, MN, USA), following the manufacturer’s protocols. ..

    Article Title: NET degradation attenuates ricin-induced acute lung injury and protects mice from ARDS.
    Article Snippet: .. Interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), keratinocyte chemoattractant (KC), macrophage inflammatory protein-2 (MIP-2), Interleukin-1β (IL-1β), monocyte chemoattractant protein (MCP-1), vascular endothelial growth factor (VEGF) and tumor necrosis factor-α (TNF-α) were quantified using ELISA kits (R&D Systems, USA), following the manufacturer’s instructions. .. Tailormade Luminex mouse discovery assay was performed for measurement of the following mediators: C1qR1/CD93, CCL11/Eotaxin, CCL22/MDC, Chitinase 3-like 1/YKL40, CXCL16, HGF, IL-1α/IL-1F1, IL-10, IL-13, MMP-9, Osteopontin, Periostin/OSF-2, Resistin, S100A9, Serpin E1/PAI-1, Thrombospondin-4, TIMP-1, Dkk-1, EMMPRIN/CD147 and LIX (R&D Systems, Biotest, USA).

    Clinical Proteomics:

    Article Title: Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis.
    Article Snippet: .. Measurement of soluble immunosuppressive factors The levels of soluble immunosuppressive factors, including matrix metalloproteinase (MMP)-1, MMP-2, and MMP-7, transforming growth factor-beta 1 (TGF-β1), hepatocyte growth factor (HGF), E-cadherin, vascular endothelial growth factor (VEGF), and angiopoietin-2 (ANGPT-2), were quantified [10-12,14-17]. https://doi.org/10.5230/jgc.2025.25.e46https://jgc-online.org Plasma and ascites supernatants were analyzed for these factors using commercially available ELISA kits (Quantikine; R&D Systems, Minneapolis, MN, USA), following the manufacturer’s protocols. ..

    Concentration Assay:

    Article Title: The TGF-β1-oxidative stress axis underlies accelerated senescence of endothelial cells exposed to serum from hypertensive patients.
    Article Snippet: Background: There is a bidirectional link between hypertension (HT) and cellular senescence of endothelial cells (ECs).. However, the mechanisms underlying EC senescence in patients with HT are not yet fully understood.. Methods and Results: We analyzed serum from 71 patients with primary HT and compared it to serum from 25 healthy donors to assess its effects on EC biology, including biomarkers, signaling pathways, and cellular senescence effectors.



    Similar Products

    vascular endothelial growth factor vegf protein  (MedChemExpress)
    95
    MedChemExpress vascular endothelial growth factor vegf protein
    Schematic illustration of the a) preparation and application of Ti-OH-ePV; b) <t>VEGF</t> release of Ti-OH-ePV under different pH conditions; c) anastomotic healing performance with Ti and Ti-OH-ePV; d) healing-promotion mechanism of Ti-OH-ePV.
    Vascular Endothelial Growth Factor Vegf Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/eNOS+Antibody/pmc12856637-192-0-9
    Average 95 stars, based on 1 article reviews
    vascular endothelial growth factor vegf protein - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    vegf  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology vegf
    Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, <t>VEGF,</t> HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.
    Vegf, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/Rat+VEGF-A+(Vascular+Endothelial+Cell+Growth+Factor+A)+ELISA+Kit/pmc12992994-233-11-23
    Average 94 stars, based on 1 article reviews
    vegf - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    vascular endothelial growth factor  (R&D Systems)
    96
    R&D Systems vascular endothelial growth factor
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Vascular Endothelial Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/Human+VEGF+DuoSet+ELISA/pmc12926579-106-14-25
    Average 96 stars, based on 1 article reviews
    vascular endothelial growth factor - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    recombinant human vegf 165 protein  (Bio-Techne corporation)
    97
    Bio-Techne corporation recombinant human vegf 165 protein
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Recombinant Human Vegf 165 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/Recombinant+Human+VEGF+165+Protein/bio-techne+corporation___293-ve
    Average 97 stars, based on 1 article reviews
    recombinant human vegf 165 protein - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    vascular endothelial growth factor a vegfa  (Proteintech)
    96
    Proteintech vascular endothelial growth factor a vegfa
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Vascular Endothelial Growth Factor A Vegfa, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/VEGFA+Fusion+Protein/pmc12914112-62-58-64
    Average 96 stars, based on 1 article reviews
    vascular endothelial growth factor a vegfa - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    vascular endothelial growth factor conundrum  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health vascular endothelial growth factor conundrum
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Vascular Endothelial Growth Factor Conundrum, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/anti+retroviral+therapy/10__4103_slash_ijo__ijo_3217_25-4-13-9
    Average 86 stars, based on 1 article reviews
    vascular endothelial growth factor conundrum - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    vascular endothelial growth factor a vegf a  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology vascular endothelial growth factor a vegf a
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Vascular Endothelial Growth Factor A Vegf A, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/Human+VEGF-A+(Vascular+Endothelial+Cell+Growth+Factor+A)+ELISA+Kit/pm42020886-106-17-23
    Average 95 stars, based on 1 article reviews
    vascular endothelial growth factor a vegf a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    human vascular endothelial growth factor 165  (R&D Systems)
    96
    R&D Systems human vascular endothelial growth factor 165
    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and <t>VEGF</t> expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
    Human Vascular Endothelial Growth Factor 165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vascular+endothelial+growth+factor+vegf/Recombinant+Human+VEGF+165+Protein/pm41977310-161-11-21
    Average 96 stars, based on 1 article reviews
    human vascular endothelial growth factor 165 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Schematic illustration of the a) preparation and application of Ti-OH-ePV; b) VEGF release of Ti-OH-ePV under different pH conditions; c) anastomotic healing performance with Ti and Ti-OH-ePV; d) healing-promotion mechanism of Ti-OH-ePV.

    Journal: Bioactive Materials

    Article Title: Bioactive-coated porous anastomotic staples enhance anastomotic healing

    doi: 10.1016/j.bioactmat.2026.01.005

    Figure Lengend Snippet: Schematic illustration of the a) preparation and application of Ti-OH-ePV; b) VEGF release of Ti-OH-ePV under different pH conditions; c) anastomotic healing performance with Ti and Ti-OH-ePV; d) healing-promotion mechanism of Ti-OH-ePV.

    Article Snippet: Vascular Endothelial Growth Factor (VEGF) protein was supplied by MedChemExpress LLC (USA).

    Techniques:

    Structure characterization of Ti-OH-ePV. a) SEM images of Ti, Ti-OH, and Ti-OH-ePV (scale bars: 1 μm); b) Elemental mapping of Ti-OH-ePV; c) CV test of DA and VEGF solution under a nitrogen atmosphere; d) AFM height images of Ti, Ti-OH, and Ti-OH-ePV; e) Surface Sa (arithmetic mean height) via AFM of Ti, Ti-OH, and Ti-OH-ePV; f) Water contact angle of Ti, Ti-OH, and Ti-OH-ePV; g) FTIR spectra of Ti, Ti-OH, and Ti-OH-ePV; h) Tensile testing of the Ti, Ti-OH, and Ti-OH-ePV; i) Single anastomotic staple tensile strength testing of the Ti, Ti-OH, and Ti-OH-ePV; j) VEGF release profiles of the Ti-OH-ePV, Ti-ePV, and Ti-OH-PV in buffer solutions at pH = 7.4; k) VEGF release profiles of the Ti-OH-ePV, Ti-ePV, and Ti-OH-PV in buffer solutions at pH = 6.5; n = 3; ns = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: Bioactive Materials

    Article Title: Bioactive-coated porous anastomotic staples enhance anastomotic healing

    doi: 10.1016/j.bioactmat.2026.01.005

    Figure Lengend Snippet: Structure characterization of Ti-OH-ePV. a) SEM images of Ti, Ti-OH, and Ti-OH-ePV (scale bars: 1 μm); b) Elemental mapping of Ti-OH-ePV; c) CV test of DA and VEGF solution under a nitrogen atmosphere; d) AFM height images of Ti, Ti-OH, and Ti-OH-ePV; e) Surface Sa (arithmetic mean height) via AFM of Ti, Ti-OH, and Ti-OH-ePV; f) Water contact angle of Ti, Ti-OH, and Ti-OH-ePV; g) FTIR spectra of Ti, Ti-OH, and Ti-OH-ePV; h) Tensile testing of the Ti, Ti-OH, and Ti-OH-ePV; i) Single anastomotic staple tensile strength testing of the Ti, Ti-OH, and Ti-OH-ePV; j) VEGF release profiles of the Ti-OH-ePV, Ti-ePV, and Ti-OH-PV in buffer solutions at pH = 7.4; k) VEGF release profiles of the Ti-OH-ePV, Ti-ePV, and Ti-OH-PV in buffer solutions at pH = 6.5; n = 3; ns = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: Vascular Endothelial Growth Factor (VEGF) protein was supplied by MedChemExpress LLC (USA).

    Techniques:

    a) The procedure of gastrointestinal anastomosis in New Zealand rabbit; b) Immumohistochemical staining images of IL-6, TNF-α, TGF-β, and IL-10 at the anastomotic stoma on day 3 for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups (scale bar: 25 μm); c) Statistical analysis of IL-6 expression in different groups; d) Statistical analysis of TNF-α expression in different groups; e) Statistical analysis of TGF-β expression in different groups; f) Statistical analysis of IL-10 expression in different groups; n = 3; ns = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: Bioactive Materials

    Article Title: Bioactive-coated porous anastomotic staples enhance anastomotic healing

    doi: 10.1016/j.bioactmat.2026.01.005

    Figure Lengend Snippet: a) The procedure of gastrointestinal anastomosis in New Zealand rabbit; b) Immumohistochemical staining images of IL-6, TNF-α, TGF-β, and IL-10 at the anastomotic stoma on day 3 for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups (scale bar: 25 μm); c) Statistical analysis of IL-6 expression in different groups; d) Statistical analysis of TNF-α expression in different groups; e) Statistical analysis of TGF-β expression in different groups; f) Statistical analysis of IL-10 expression in different groups; n = 3; ns = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: Vascular Endothelial Growth Factor (VEGF) protein was supplied by MedChemExpress LLC (USA).

    Techniques: Staining, Expressing

    a) Immumohistochemical staining images of CD31 on day 7 at the anastomotic stoma for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups (scale bar: 25 μm); b) Masson staining images on day 14 at the anastomotic stoma for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups (scale bar: 20 μm); c) H&E staining images on day 14 at the anastomotic stoma for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups; d) Statistical analysis for the number of blood vessels in different groups; e) Statistical analysis of collagen expression in different groups; f) Statistical analysis of bursting pressure on days 7, and 14 in different groups; g) Statistical analysis of WBC on days pre-1, 3, 7, and 14 in different groups; h) Statistical analysis of APTT on days pre-1, 3, 7, and 14 in different groups; i) Statistical analysis of ALT on days pre-1, 3, 7, and 14 in different groups; n = 3; ns = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: Bioactive Materials

    Article Title: Bioactive-coated porous anastomotic staples enhance anastomotic healing

    doi: 10.1016/j.bioactmat.2026.01.005

    Figure Lengend Snippet: a) Immumohistochemical staining images of CD31 on day 7 at the anastomotic stoma for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups (scale bar: 25 μm); b) Masson staining images on day 14 at the anastomotic stoma for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups (scale bar: 20 μm); c) H&E staining images on day 14 at the anastomotic stoma for Ti, Ti-OH, Ti-OH-ePDA (PDA-only), and Ti-OH-ePV (VEGF-loaded PDA) groups; d) Statistical analysis for the number of blood vessels in different groups; e) Statistical analysis of collagen expression in different groups; f) Statistical analysis of bursting pressure on days 7, and 14 in different groups; g) Statistical analysis of WBC on days pre-1, 3, 7, and 14 in different groups; h) Statistical analysis of APTT on days pre-1, 3, 7, and 14 in different groups; i) Statistical analysis of ALT on days pre-1, 3, 7, and 14 in different groups; n = 3; ns = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: Vascular Endothelial Growth Factor (VEGF) protein was supplied by MedChemExpress LLC (USA).

    Techniques: Staining, Expressing

    Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, VEGF, HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.

    Journal: Bioactive Materials

    Article Title: Mesenchymal stromal cells-loaded 3D radially aligned composite scaffold with potentiated paracrine signaling for sequential bone regeneration

    doi: 10.1016/j.bioactmat.2026.02.059

    Figure Lengend Snippet: Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, VEGF, HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.

    Article Snippet: ELISA kits for PGE2 (Cat. No. E-EL-0034), TGF-β (Cat. No. E-EL-0162), VEGF (Cat. No. E-EL-R2603), and HGF (Cat. No. E-EL-R0496) were purchased from Elabscience (Wuhan, China).

    Techniques: Confocal Microscopy, Fluorescence, Staining, Cell Culture, Expressing

    Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

    Journal: Bioactive Materials

    Article Title: Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing

    doi: 10.1016/j.bioactmat.2026.02.004

    Figure Lengend Snippet: Non-polarised (M0) macrophages grown on CG-155-i scaffolds are driven towards an anti-inflammatory (M2) phenotype. A-B) Assessment of cell viability using metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Gene expression analysis of miRNA-155 and downstream genes demonstrate the activation of anti-inflammatory processes following miRNA-155 inhibition via SHIP1 and SOCS1. F-J) Marker analysis of pro-inflammatory M1 macrophage phenotype (NOS2, CD80, and CD86) and anti-inflammatory M2 phenotype (ARG-1 and CD206) highlight a clear modulation of macrophage polarisation towards an anti-inflammatory state in CG-155-i scaffolds as evidence by decreased NOS2 and CD80 and upregulated ARG1. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

    Article Snippet: Human tumour necrosis factor-alpha (TNF-α, Cat # DY210), interleukin 10 (IL-10, Cat #DY217B), and vascular endothelial growth factor (VEGF, Cat # DY 293B) ELISA kits (R&D Systems, USA) were used to quantify the protein release from cells transfected on miRNA-i-activated scaffolds.

    Techniques: Activity Assay, Gene Expression, Activation Assay, Inhibition, Marker, Expressing

    Pro-inflammatory (M1) macrophages are driven towards an anti-inflammatory (M2) phenotype on CG-155-i scaffolds. A-B) Assessment of cell viability through metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Scaffold-mediated inhibition of miRNA-155 in pro-inflammatory macrophages maintains SHIP1 and SOCS1 upregulation despite the enhanced inflammatory environment. F-H) NOS2 expression shows a trending decrease while CD80 and CD86 levels are downregulated on the CG-155-i scaffolds. I-J) Scaffold-mediated miRNA-155 inhibition does not significantly alter ARG1 expression whereas CD206 is still upregulated, highlighted an M2 macrophage polarisation despite the inflammatory cues. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

    Journal: Bioactive Materials

    Article Title: Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing

    doi: 10.1016/j.bioactmat.2026.02.004

    Figure Lengend Snippet: Pro-inflammatory (M1) macrophages are driven towards an anti-inflammatory (M2) phenotype on CG-155-i scaffolds. A-B) Assessment of cell viability through metabolic activity and DNA content showed increased macrophage activity and proliferation on the CG-155-i group over 7 days. C-E) Scaffold-mediated inhibition of miRNA-155 in pro-inflammatory macrophages maintains SHIP1 and SOCS1 upregulation despite the enhanced inflammatory environment. F-H) NOS2 expression shows a trending decrease while CD80 and CD86 levels are downregulated on the CG-155-i scaffolds. I-J) Scaffold-mediated miRNA-155 inhibition does not significantly alter ARG1 expression whereas CD206 is still upregulated, highlighted an M2 macrophage polarisation despite the inflammatory cues. K-P) Quantification of TNF-α, IL-10, and VEGF expression at post-transcriptional and post-translational levels further evidences the M2 polarisation of macrophages on CG-155-i scaffolds as shown by IL-10 and VEGF upregulation. Data shows mean ± SD (n = 5), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

    Article Snippet: Human tumour necrosis factor-alpha (TNF-α, Cat # DY210), interleukin 10 (IL-10, Cat #DY217B), and vascular endothelial growth factor (VEGF, Cat # DY 293B) ELISA kits (R&D Systems, USA) were used to quantify the protein release from cells transfected on miRNA-i-activated scaffolds.

    Techniques: Activity Assay, Inhibition, Expressing

    Secretome from macrophages cultured on CG-155-i scaffolds induces anti-inflammatory responses on endothelial cells. A) Cytokine profile analysis revealed an increased release of pro-angiogenic and anti-inflammatory growth factors from macrophages on CG-155-i scaffolds. B-E) Endothelial cells exposed to M0 macrophage secretome show a reduced expression of pro-inflammatory ICAM in the CG-155-i group. F-I) M1 macrophage secretome on endothelial cells elicits clear morphological changes and decreased ICAM intensity in the CG-155-i group. Scale bars = 100 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01.

    Journal: Bioactive Materials

    Article Title: Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing

    doi: 10.1016/j.bioactmat.2026.02.004

    Figure Lengend Snippet: Secretome from macrophages cultured on CG-155-i scaffolds induces anti-inflammatory responses on endothelial cells. A) Cytokine profile analysis revealed an increased release of pro-angiogenic and anti-inflammatory growth factors from macrophages on CG-155-i scaffolds. B-E) Endothelial cells exposed to M0 macrophage secretome show a reduced expression of pro-inflammatory ICAM in the CG-155-i group. F-I) M1 macrophage secretome on endothelial cells elicits clear morphological changes and decreased ICAM intensity in the CG-155-i group. Scale bars = 100 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01.

    Article Snippet: Human tumour necrosis factor-alpha (TNF-α, Cat # DY210), interleukin 10 (IL-10, Cat #DY217B), and vascular endothelial growth factor (VEGF, Cat # DY 293B) ELISA kits (R&D Systems, USA) were used to quantify the protein release from cells transfected on miRNA-i-activated scaffolds.

    Techniques: Cell Culture, Expressing

    Secretome from macrophages on CG-155-i scaffolds enhances endothelial cell migration and organisation into vascular-like structures under chronic-like conditions. A) Endothelial cells exposed to M1 macrophage secretome show reduced migration rates compared to M0 conditions. B-C) Analysis of migration profiles under M0 conditions did not reveal any clear differences in behaviour between treatment groups. D-E) Endothelial cell migration rate exposed to secretome from M1 macrophages on CG-155-i scaffolds result in faster cell migration compared to the negative and miRNA-free groups after 24 h. E) Endothelial cells show higher vascular-like organisation when exposed to M0 macrophage secretome. F-H) Secretome from CG-155-i scaffolds enables improved vascular-like complexity in both M0 and M1 conditions. Scale bars = 500 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p > 0.001, and ∗∗∗∗p < 0.0001.

    Journal: Bioactive Materials

    Article Title: Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing

    doi: 10.1016/j.bioactmat.2026.02.004

    Figure Lengend Snippet: Secretome from macrophages on CG-155-i scaffolds enhances endothelial cell migration and organisation into vascular-like structures under chronic-like conditions. A) Endothelial cells exposed to M1 macrophage secretome show reduced migration rates compared to M0 conditions. B-C) Analysis of migration profiles under M0 conditions did not reveal any clear differences in behaviour between treatment groups. D-E) Endothelial cell migration rate exposed to secretome from M1 macrophages on CG-155-i scaffolds result in faster cell migration compared to the negative and miRNA-free groups after 24 h. E) Endothelial cells show higher vascular-like organisation when exposed to M0 macrophage secretome. F-H) Secretome from CG-155-i scaffolds enables improved vascular-like complexity in both M0 and M1 conditions. Scale bars = 500 μm. Data shows mean ± SD (n = 4), ∗ indicates p < 0.05, ∗∗p < 0.01, ∗∗∗p > 0.001, and ∗∗∗∗p < 0.0001.

    Article Snippet: Human tumour necrosis factor-alpha (TNF-α, Cat # DY210), interleukin 10 (IL-10, Cat #DY217B), and vascular endothelial growth factor (VEGF, Cat # DY 293B) ELISA kits (R&D Systems, USA) were used to quantify the protein release from cells transfected on miRNA-i-activated scaffolds.

    Techniques: Migration